- Home
- RZLT vs DCTH Comparison
RZLT vs DCTH Comparison
Compare RZLT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLT
- DCTH
- Stock Information
- Founded
- RZLT 2010
- DCTH 1988
- Country
- RZLT United States
- DCTH United States
- Employees
- RZLT N/A
- DCTH N/A
- Industry
- RZLT Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- RZLT Health Care
- DCTH Health Care
- Exchange
- RZLT Nasdaq
- DCTH Nasdaq
- Market Cap
- RZLT 292.0M
- DCTH 379.5M
- IPO Year
- RZLT N/A
- DCTH N/A
- Fundamental
- Price
- RZLT $5.18
- DCTH $11.87
- Analyst Decision
- RZLT Strong Buy
- DCTH Strong Buy
- Analyst Count
- RZLT 8
- DCTH 4
- Target Price
- RZLT $11.63
- DCTH $21.50
- AVG Volume (30 Days)
- RZLT 393.1K
- DCTH 489.1K
- Earning Date
- RZLT 11-07-2024
- DCTH 11-08-2024
- Dividend Yield
- RZLT N/A
- DCTH N/A
- EPS Growth
- RZLT N/A
- DCTH N/A
- EPS
- RZLT N/A
- DCTH N/A
- Revenue
- RZLT N/A
- DCTH $22,644,000.00
- Revenue This Year
- RZLT N/A
- DCTH $1,605.13
- Revenue Next Year
- RZLT N/A
- DCTH $111.67
- P/E Ratio
- RZLT N/A
- DCTH N/A
- Revenue Growth
- RZLT N/A
- DCTH 945.91
- 52 Week Low
- RZLT $0.76
- DCTH $2.84
- 52 Week High
- RZLT $6.19
- DCTH $12.88
- Technical
- Relative Strength Index (RSI)
- RZLT 49.97
- DCTH 61.82
- Support Level
- RZLT $4.90
- DCTH $11.42
- Resistance Level
- RZLT $5.53
- DCTH $12.79
- Average True Range (ATR)
- RZLT 0.35
- DCTH 0.66
- MACD
- RZLT 0.01
- DCTH 0.15
- Stochastic Oscillator
- RZLT 59.77
- DCTH 74.17
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.